CFMS - ConforMISAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $0.76 | Open | $0.74 |
| Volume | 67.4K | Market Cap | 243.01M |
| Yield | Last Dividend |
| Conformis up 6% premarket after prelimin... | 07/06/20 |
| Conformis (NASDAQ:CFMS) sees Q2 total revenue of ~$19.5M (-1% Y/Y), Product revenue of ~$9.7M (-50% Y/Y). CFMS expects royalty revenue of $9.7M, inclu... | |
| Conformis Reports Preliminary Second Qua... | 07/06/20 |
| Earnings Call to be Hosted on August 5, 2020 BILLERICA, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology??... | |
| Zimmer Biomet : Conformis Settles Patent... | 05/28/20 |
| By Chris Wack Conformis Inc. said it has entered into a settlement and license agreement with Zimmer Biomet Holdings Inc., Zimmer Inc., Zimmer US Inc.... | |
| ConforMIS (CFMS) May Report Negative Ear... | 04/29/20 |
| ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with... | |
| Global Knee Replacement Market 2020-2024... | 01/14/20 |
| LONDON--(BUSINESS WIRE)-- #Healthcare--The global knee replacement market is expected to grow by USD 2.26 billion during 2020-2024, progressing at a C... | |
| Hedge Funds Are Buying ConforMIS, Inc. (... | 12/16/19 |
| Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, ... | |
| -$0.10 EPS Expected for ConforMIS Inc (N... | 11/16/19 |
| Analysts predict that ConforMIS Inc (NASDAQ:CFMS) will report ($0.10) earnings per share (EPS) for the current fiscal quarter, according to Zacks Inve... | |
| Global Knee Replacement Market 2020-2024... | 11/06/19 |
| LONDON--(BUSINESS WIRE)-- #healthcare--Technavio has been monitoring the global knee replacement market and the market is poised to grow by USD 2.26 b... | |
| Will ConforMIS (CFMS) Report Negative Ea... | 10/23/19 |
| ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with... | |
| Conformis and Stryker Execute Developmen... | 10/01/19 |
| Conformis, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and ... | |
| Week 21 Breakout Forecast: Short-Term Pi... | 05/18/19 |
| No summary available. | |
| Week 20 Breakout Forecast: Short-Term Pi... | 05/13/19 |
| No summary available. | |
| Conformis' (CFMS) CEO Mark Augusti on Q1... | 05/01/19 |
| Conformis, Inc. (NASDAQ:CFMS) Q1 2019 Earnings Conference Call May 1, 2019 4:30 PM ET Company Participants Mark Augusti ??? President and Chief Execut... | |
| ConforMIS (CFMS) Reports Q1 Loss, Tops R... | 05/01/19 |
| ConforMIS (CFMS) delivered earnings and revenue surprises of 0.00% and 2.64%, respectively, for the quarter ended March 2019. Do the numbers hold clue... | |
| ConforMIS EPS in-line, beats on revenue | 05/01/19 |
| No summary available. | |
| Can iTotal PS Revenues Drive ConforMIS' ... | 04/25/19 |
| ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties. | |
| ConforMIS (CFMS) May Report Negative Ear... | 04/24/19 |
| ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with... | |
| Conformis Is A Failed Market Experiment,... | 04/11/19 |
| No summary available. | |
| ZUO, NOK and JKS among premarket losers | 03/22/19 |
| No summary available. | |
| INO, MBT and IGC among premarket gainers | 03/21/19 |
| No summary available. | |
| Conformis poised to add to rally, up 8% ... | 03/21/19 |
| No summary available. | |
| SPWR, UNIT, and GES among notable after ... | 03/20/19 |
| No summary available. | |
| Sorrento Therapeutics and Altimmune amon... | 03/19/19 |
| No summary available. | |
| The 3D designed Conformis Hip System Ann... | 03/13/19 |
| BILLERICA, Mass., March 13, 2019 (GLOBE NEWSWIRE) -- Conformis Inc. (NASDAQ: CFMS ), a medical technology company that uses its proprietary iFit Image... | |
| Mallinckrodt and Aerie Pharmaceuticals a... | 02/26/19 |
| No summary available. | |
| CHF Solutions and MediciNova among healt... | 02/19/19 |
| No summary available. | |
| CHF Solutions and MediciNova among healt... | 02/19/19 |
| No summary available. | |
| Conformis and Avadel Pharmaceuticals amo... | 02/15/19 |
| No summary available. | |
| ConforMIS (CFMS) CEO Mark Augusti on Q4 ... | 02/06/19 |
| No summary available. | |
| ConforMIS beats by $0.03, beats on reven... | 02/06/19 |
| No summary available. | |
| Strong Buy rating | 05/12/20 |
| Oppenheimer maintains Outperform rating and lowers Price Target from $3.50 to $3.00 | |
| Date | Today (AMC) | Est. (EPS/Rev.) | ($0.10)/ 9.43M |
| Actual (EPS/Rev.) | / | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Swing Trading Cheap Stocks <~ $10 | Michael S. DeVries | 65.00 % | Follow |
| Swingers Corner | Akemi Mokoto | 42.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
